Navigation Links
Liraglutide provides significantly better glucose control than,insulin glargine in phase 3 study

er the past 2-3 months and a decrease is therefore a measure of treatment effect. The higher the blood glucose the more glucose binds to haemoglobin (glycation).

Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 23,600 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.

Further information:
Media: Investors:
Outside North America: Outside North America:
Elin K Hansen Mads Veggerby Lausten
Tel (direct):
(+45) 4442 3450 Tel (direct):
(+45) 4443 7919
ekh@novonordisk.com mlau@novonordisk.com

Katrine Sperling Hans Rommer
Tel (mobile):
(+45) 3079 6718 Tel (direct):
(+45) 4442 4765
krsp@novonordisk.com hrmm@novonordisk.com

In North America: In North America:
Sean Clements Christian Qvist Frandsen
Tel (direct):
(+1) 609 514 8316 Tel (direct):
(+1) 609 919 7937
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
2. Positive results from placebo-controlled phase IIa study in patients suffering from house dust mite allergy
3. Placebo-controlled Phase IIa Study with the Immunotherapeutic CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in Hay Fever Patients
4. Independent publication supports the profile of CeNeS phase II compound, CNS 5161
5. Isotechnikas independent data monitoring committee conducts review of phase 2b kidney transplant trial
6. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
7. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
8. 2007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion
Post Your Comments:
(Date:12/17/2014)... -- Revenue and earnings above the previous year ... In the past 2013/14 fiscal year (ended 30 ... EUR 4.287 billion (last year: EUR 4.190 billion) despite unfavorable ... 360 million. "Overall, 2013/14 was a successful fiscal year for ... and CEO of Carl Zeiss AG. "Thanks to our broad ...
(Date:12/17/2014)...  Beamz Interactive, Inc. (OTCQB: BZIC), a leading ... that it has signed an agreement with RSL ... innovative prosthetic, orthotic and assistive technology products and ... RSL Steeper will promote and supply the Beamz ... within UK residential care facilities through its Assistive ...
(Date:12/17/2014)... , Dec. 17, 2014  RXi Pharmaceuticals Corporation ... focused on discovering, developing and commercializing innovative therapies ... today announced completion of enrollment in its first Phase ... 3-month observations confirmed the 1-month findings that were ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , ...
Breaking Medicine Technology:ZEISS Asserts its Position in Difficult Environment 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5
... 2010 Phytomedics, Inc., a transformational healthcare company ... products solely derived from plant sources, announced today ... the amount of $244,000 under the Qualifying Therapeutic ... of its lead product PMI-001 for Rheumatoid Arthritis. ...
... Nov. 9, 2010 NewCardio, Inc. (OTC Bulletin Board: ... announced today that Dr. Samuel George, NewCardio,s Senior Medical ... a blinded "testing" dataset, conducted independently by the Cardiac ... to be held on December 9, 2010, at the ...
Cached Medicine Technology:Phytomedics, Inc. Awarded QTDP Grant from U.S. Department of Health and Human Services 2NewCardio to Present Results of QTinno Performance on Cardiac Safety Research Consortium Blinded 'Testing' Dataset 2NewCardio to Present Results of QTinno Performance on Cardiac Safety Research Consortium Blinded 'Testing' Dataset 3NewCardio to Present Results of QTinno Performance on Cardiac Safety Research Consortium Blinded 'Testing' Dataset 4
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... Model Compliance Guidance , , ... Compliance Association (HCCA) announced today that it will hold ... in Scottsdale, Arizona. The HCCA,s Managed Care Compliance conference, ... to provide essential information for individuals involved with managing ...
... Calif., Dec. 4 Microchip Biotechnologies, a private company ... announced today that Ezra Van Gelder has joined its ... , Ezra Van Gelder brings ... development from the life science, medical device and semiconductor ...
... LAKE CITY, Dec. 4 The Ensign Group, Inc.,(Nasdaq: ... Ensign(TM) group of skilled nursing,rehabilitative care services and assisted ... of Infinia at Alta, an 85-bed skilled,nursing facility in ... Alta,Care & Rehabilitation Center. , ...
... can become,stressful for many families -- the pressure to find ... and co-workers, and, this,year, the added weight of a slumping ... give the gift of companionship and joy by putting a ... "Before giving a furry friend as a gift, ...
... Drs. Samuel and Elenore Bogoch of Oncolab, Inc. have found that ... proteins*, are quantitatively related to the mortality rate in human cancer ... been reported to be quantitatively related to mortality rate. , ... ...
... Wash., Dec. 4 In the midst of ... challenges in the United States,healthcare providers from across ... corporate headquarters in Redmond, Wash., for the first ... examining,ways to apply information technology (IT) innovations to ...
Cached Medicine News:Health News:HCCA Announces Managed Care Compliance Conference, February 22-24, 2009, Scottsdale, Arizona 2Health News:HCCA Announces Managed Care Compliance Conference, February 22-24, 2009, Scottsdale, Arizona 3Health News:Ezra Van Gelder Joins Microchip Biotechnologies as Executive Vice President R&D 2Health News:The Ensign Group, Inc. Acquires Utah Skilled Nursing Facility 2Health News:A Season of Responsibility for New Pet Owners 2Health News:Cancer Mortality Increases With Cancer Cell Replikin Count 2Health News:Cancer Mortality Increases With Cancer Cell Replikin Count 3Health News:Microsoft, Penn State Hershey Medical Center Showcase Road Map to Patient Flow Efficiencies at First Healthcare Provider Symposium 2Health News:Microsoft, Penn State Hershey Medical Center Showcase Road Map to Patient Flow Efficiencies at First Healthcare Provider Symposium 3Health News:Microsoft, Penn State Hershey Medical Center Showcase Road Map to Patient Flow Efficiencies at First Healthcare Provider Symposium 4
... lathing techniques, intrinsically permeable polymers and advanced ... thickness of just 0.08 across all minus ... lenses maintain a 30% decrease in center ... eliminates stress points to reduce the chance ...
An easy-to-fit RGP daily wear lens with a unique bi-aspheric back surface design that provides excellent patient comfort and adaptation. Boston Envision contact lenses are an ideal alternative for vi...
Ophthalmic surgery stretcher. Designed for exceptional surgeon access, ideal for either superior or temporal approach....
... developed to stain intraocular membranes in vitreoretinal ... By injecting Membraneblue in an air-filled vitreous ... diluting the dye. After removal of all ... membranes can easily be distinguished from the ...
Medicine Products: